OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press3810.17650/1818-8346-2013-8-2-83-92NEW TRENDS IN MEDICAL SCIENCEНОВЫЕ НАПРАВЛЕНИЯ МЕДИЦИНСКОЙ НАУКИAntitumor activity of fullerene derivatives and their possible use for target drug deliveryПротивоопухолевая активность производных фуллерена и возможности их использования для адресной доставки лекарствOrlovaM. A.ОрловаМ. А.
Russian Federation

Химический факультет, кафедра радиохимии

TrofimovaT. P.ТрофимоваТ. П.
Russian Federation

Химический факультет, кафедра радиохимии

OrlovA. P.ОрловА. П.
Russian Federation

медико-биологический факультет, кафедра медицинских нанобиотехнологий

ShatalovO. A.ШаталовО. А.
Russian Federation

фармацевтический факультет, кафедра фармакологии

NapolovYu. K.НаполовЮ. К.
Russian Federation

фармацевтический факультет, кафедра фармакологии

SvistunovA. A.СвистуновА. А.
Russian Federation

фармацевтический факультет, кафедра фармакологии

ChekhoninV. P.ЧехонинВ. П.
Russian Federation

медико-биологический факультет, кафедра медицинских нанобиотехнологий

M.V. Lomonosov Moscow State UniversityФГБОУ ВПО «Московский государственный университет им. М.В. Ломоносова»N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииI.M. Sechenov Moscow State Medical University, Ministry of Health of RussiaГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России22052013828392220720142013https://oncohematology.abvpress.ru/ongm/article/view/38

.

,

1. Jalbout A.F., Hameed A.J., Trzaskowski B. Study of the structural and electronic properties of 1-(4, 5 and 6-selenenyl derivatives-3-formyl-phenyl) pyrrolidinofullerenes. J Organometal Chem 2007;692:1039–47.Jalbout A.F., Hameed A.J., Trzaskowski B. Study of the structural and electronic properties of 1-(4, 5 and 6-selenenyl derivatives-3-formyl-phenyl) pyrrolidinofullerenes. J Organometal Chem 2007;692:1039–47.2. Jiao F., Liu Y., Qu Y. et al. Studies on antitumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon 2010;48:2231–43.Jiao F., Liu Y., Qu Y. et al. Studies on antitumor and antimetastatic activities of fullerenol in a mouse breast cancer model. Carbon 2010;48:2231–43.3. Nishizawa C., Hashimoto N., Yokoo S. et al. Pyrrolidinium-type fullerene derivativeinduced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radic Res 2009;43:1240–7.Nishizawa C., Hashimoto N., Yokoo S. et al. Pyrrolidinium-type fullerene derivativeinduced apoptosis by the generation of reactive oxygen species in HL-60 cells. Free Radic Res 2009;43:1240–7.4. Wang J., Chen C., Li B. et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumorbearing mice. Biochem Pharmacol 2006;71:872–81.Wang J., Chen C., Li B. et al. Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumorbearing mice. Biochem Pharmacol 2006;71:872–81.5. Liu Y., Jiao F., Qiu Y. et al. Immunostimulatory properties and enhanced TNF-a mediated cellularLiu Y., Jiao F., Qiu Y. et al. Immunostimulatory properties and enhanced TNF-a mediated cellularimmunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology 2009;20:415102–11.6. Liu Y., Jiao F., Qiu Y. et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity. Biomaterials 2009;30:3934–45.Liu Y., Jiao F., Qiu Y. et al. The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-α mediated cellular immunity. Biomaterials 2009;30:3934–45.7. Meng H., Xing G., Sun B. et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. Acs Nano 2010;4:2773–83.Meng H., Xing G., Sun B. et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. Acs Nano 2010;4:2773–83.8. Prylutska S., Burlaka A.P., Klymenko P.P. et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol 2011;2:105–10.Prylutska S., Burlaka A.P., Klymenko P.P. et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nanotechnol 2011;2:105–10.9. Kharisov B.I., Kharissova O.V., Gomez M.J., Mendez U.O. Recent advances in the synthesis, characterization, and applications of fulleropyrrolidines. Ind Eng Chem Res 2009;48:545–71.Kharisov B.I., Kharissova O.V., Gomez M.J., Mendez U.O. Recent advances in the synthesis, characterization, and applications of fulleropyrrolidines. Ind Eng Chem Res 2009;48:545–71.10. Mikawa M., Kato H., Okumura M. et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001;12:510–4.Mikawa M., Kato H., Okumura M. et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001;12:510–4.11. Liu J.H., Cao L., Luo P.G. et al. Fullerene-conjugated doxorubicin in cells. Acs Appl Mater Interf 2010;2:1384–9.Liu J.H., Cao L., Luo P.G. et al. Fullerene-conjugated doxorubicin in cells. Acs Appl Mater Interf 2010;2:1384–9.12. Montellano A., Da Ros T., Bianco A., Prato M. Fullerene C60 as a multifunctional system for drug and gene delivery. Nanoscale 2011;3:4035–44.Montellano A., Da Ros T., Bianco A., Prato M. Fullerene C60 as a multifunctional system for drug and gene delivery. Nanoscale 2011;3:4035–44.13. Rancan F., Helmreich M., Molich A. et al. Fullerene-pyropheophorbide a complexes as sensitizer for photodynamic therapy: uptake and photo-induced cytotoxicity on Jurkat cells. J Photochem Photobiol B 2005;80:1–7.Rancan F., Helmreich M., Molich A. et al. Fullerene-pyropheophorbide a complexes as sensitizer for photodynamic therapy: uptake and photo-induced cytotoxicity on Jurkat cells. J Photochem Photobiol B 2005;80:1–7.14. Boyd P.D., Hodgson M.C., Rickard C.E.F. et al. Selective supramolecular porphyrin/fullerene interactions. J Am Chem Soc 1999;121:10487–95.Boyd P.D., Hodgson M.C., Rickard C.E.F. et al. Selective supramolecular porphyrin/fullerene interactions. J Am Chem Soc 1999;121:10487–95.15. Nishiyama N., Stapert H.R., Zhang G.D. et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjugate Chem 2003;14:58–66.Nishiyama N., Stapert H.R., Zhang G.D. et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjugate Chem 2003;14:58–66.16. Rezayat S.M., Boushehri S.V.S., Salmanian B. et al. The porphyrin-fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect. Eur J MedRezayat S.M., Boushehri S.V.S., Salmanian B. et al. The porphyrin-fullerene nanoparticles to promote the ATP overproduction in myocardium: 25Mg2+-magnetic isotope effect. Eur J MedChem 2009;44:1554–69.17. Buchachenko A.L., Kuznetsov D.A., Breslavskaya N.N., Orlova M.A. Magnesium isotope effect in enzymatic phosphorylation. J Phys Chem B 2008;112:2548–56.Buchachenko A.L., Kuznetsov D.A., Breslavskaya N.N., Orlova M.A. Magnesium isotope effect in enzymatic phosphorylation. J Phys Chem B 2008;112:2548–56.18. Nikolić N., Vranjes-Ethurić S., Janković D. et al. Preparation and biodistribution of radiolabeled fullerene C60 nanocrystals. Nanotechnol 2009;20:385102.Nikolić N., Vranjes-Ethurić S., Janković D. et al. Preparation and biodistribution of radiolabeled fullerene C60 nanocrystals. Nanotechnol 2009;20:385102.19. Zhou Z., Lenk R.P., Dellinger A. et al. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconj Chem 2010;21:1656–61.Zhou Z., Lenk R.P., Dellinger A. et al. Liposomal formulation of amphiphilic fullerene antioxidants. Bioconj Chem 2010;21:1656–61.20. Chaudhuri P., Paraskar A., Soni S. et al. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009;3: 2505–14.Chaudhuri P., Paraskar A., Soni S. et al. Fullerenol-cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009;3: 2505–14.21. Song H., Luo S., Wei H. et al. In vivo biological behavior of 99mTc(CO)3 labelled fullerol. J Radioanal Nucl Chem 2010;285:635–9.Song H., Luo S., Wei H. et al. In vivo biological behavior of 99mTc(CO)3 labelled fullerol. J Radioanal Nucl Chem 2010;285:635–9.22. Roberts J.E., Wielgus A.R., Boyes W.K. et al. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol Appl Pharmacol 2008;228: 49–58.Roberts J.E., Wielgus A.R., Boyes W.K. et al. Phototoxicity and cytotoxicity of fullerol in human lens epithelial cells. Toxicol Appl Pharmacol 2008;228: 49–58.23. Zhao B., Yin J.J., Bilski P. et al. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol 2009;241:163–72.Zhao B., Yin J.J., Bilski P. et al. Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol 2009;241:163–72.24. Prow T.W., Bhutto I., Kim S.Y. et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340–9.Prow T.W., Bhutto I., Kim S.Y. et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008;4:340–9.25. Bejjani R.A., Benezra D., Cohen H. et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005;17:124–32.Bejjani R.A., Benezra D., Cohen H. et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 2005;17:124–32.26. Мешалкин Ю.П., Бгатова Н.Р. Перспективы и проблемы использования неорганических материалов в онкологии. Ж Сиб Фед Ун-та В 2008;3:248–68.Мешалкин Ю.П., Бгатова Н.Р. Перспективы и проблемы использования неорганических материалов в онкологии. Ж Сиб Фед Ун-та В 2008;3:248–68.27. Mroz P., Tegos G.P., Gali H. et al. Photodynamic therapy with fullerenes. Photochem Photobiol Sci 2007;6:1139–49.Mroz P., Tegos G.P., Gali H. et al. Photodynamic therapy with fullerenes. Photochem Photobiol Sci 2007;6:1139–49.28. Burlaka A.P., Sidorik U.P., Pryl 2004;26:326–7.Burlaka A.P., Sidorik U.P., Pryl 2004;26:326–7.29. Mroz P., Pawlak A., Satti M. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radical Biol Med 2007;43:711–9.Mroz P., Pawlak A., Satti M. Functionalized fullerenes mediate photodynamic killing of cancer cells: Type I versus Type II photochemical mechanism. Free Radical Biol Med 2007;43:711–9.30. Yano S., Hirohara S., Obata M. et al. Current states and future views inphotodynamic therapy. J Photochem Photobiol C 2011;12:46–67.Yano S., Hirohara S., Obata M. et al. Current states and future views inphotodynamic therapy. J Photochem Photobiol C 2011;12:46–67.31. Hu Z., Zhang C., Huang Y. et al. Photodynamic anticancer activities of water-soluble C60 derivatives nd their biological consequences in a HeLa cell line. Chem Biol Inter 2012;195:86–94.Hu Z., Zhang C., Huang Y. et al. Photodynamic anticancer activities of water-soluble C60 derivatives nd their biological consequences in a HeLa cell line. Chem Biol Inter 2012;195:86–94.32. Liu J., Ohta S., Sonoda A. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Controlled Release 2007;117:104–10.Liu J., Ohta S., Sonoda A. Preparation of PEG-conjugated fullerene containing Gd3+ ions for photodynamic therapy. J Controlled Release 2007;117:104–10.33. Jiang G., Li G. Preparation, characterization, and properties of fullerene–vinylpyrrolidone copolymers. Biotechnol Prog 2012;28:215–22.Jiang G., Li G. Preparation, characterization, and properties of fullerene–vinylpyrrolidone copolymers. Biotechnol Prog 2012;28:215–22.34. Vileno B., Jeney S., Sienkiewicz A. et al. Evidence of lipid peroxidation and protein phosphorylation in cells upon oxidative stress photo-generated by fullerols. Biophys Chem 2010;152:164–9.Vileno B., Jeney S., Sienkiewicz A. et al. Evidence of lipid peroxidation and protein phosphorylation in cells upon oxidative stress photo-generated by fullerols. Biophys Chem 2010;152:164–9.35. Badireddy A.R., Hotze E.M., Chellam S. et al. Inactivation of bacteriophages via photosensitization of fullerol nanoparticles. Environ Sci Technol 2007;41:6627–32.Badireddy A.R., Hotze E.M., Chellam S. et al. Inactivation of bacteriophages via photosensitization of fullerol nanoparticles. Environ Sci Technol 2007;41:6627–32.36. Taroni P., D’Andrea C., Valentini G. et al. Fullerol in human lens and retinal pigment epithelial cells: time domain fluorescence spectroscopy and imaging. Photochem Photobiol Sci 2011;10:904–10.Taroni P., D’Andrea C., Valentini G. et al. Fullerol in human lens and retinal pigment epithelial cells: time domain fluorescence spectroscopy and imaging. Photochem Photobiol Sci 2011;10:904–10.37. Straface E., Santini M.T., Donelli G. et al. Vitamin E prevents UVB-induced cell blebbing and cell death in A431 epidermoid cells. Int J Rad Biol 1995;68:579–87.Straface E., Santini M.T., Donelli G. et al. Vitamin E prevents UVB-induced cell blebbing and cell death in A431 epidermoid cells. Int J Rad Biol 1995;68:579–87.38. Ito S., Itoga K., Yamato M. et al. The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin. Toxicology 2010;267:27–38.Ito S., Itoga K., Yamato M. et al. The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin. Toxicology 2010;267:27–38.39. Fumelli C., Marconi A., Salvioli S. et al. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2000;115: 835–41.Fumelli C., Marconi A., Salvioli S. et al. Carboxyfullerenes protect human keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2000;115: 835–41.40. Zhao B., He Y.Y., Chignell C.F. et al. Difference in phototoxicity of cyclodextrin complexed fullerene [(γ-CyD)2/C60] and its aggregated derivatives toward human lens epithelial cells. Chem Res Toxicol 2009;22:660–7.Zhao B., He Y.Y., Chignell C.F. et al. Difference in phototoxicity of cyclodextrin complexed fullerene [(γ-CyD)2/C60] and its aggregated derivatives toward human lens epithelial cells. Chem Res Toxicol 2009;22:660–7.41. Mikata Y., Takagi S., Tanahashi M. et al. Detection of 1270 nm emission from singlet oxygen and photocytotoxic property of sugar-pendant 60 fullerenes. Bioorg Med Chem Lett 2003;13:3289–92.Mikata Y., Takagi S., Tanahashi M. et al. Detection of 1270 nm emission from singlet oxygen and photocytotoxic property of sugar-pendant 60 fullerenes. Bioorg Med Chem Lett 2003;13:3289–92.42. Otake E., Sakuma S., Torii K. et al. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. Photochem Photobiol 2010;86:1356–63.Otake E., Sakuma S., Torii K. et al. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene. Photochem Photobiol 2010;86:1356–63.43. Palyvoda K.O., Grynyuk I.I., Prylutsk S.V. et al. Apoptosis photoinduction by C60 fullerene in human leukemic T cells. Ukr Biochem J 2010;82:121–7.Palyvoda K.O., Grynyuk I.I., Prylutsk S.V. et al. Apoptosis photoinduction by C60 fullerene in human leukemic T cells. Ukr Biochem J 2010;82:121–7.44. Constantin C., Neagu M., Ion R. et al. Fullerene-porphyrin nanostructures in photodynamic therapy. Nanomedicine 2010;5:307–17.Constantin C., Neagu M., Ion R. et al. Fullerene-porphyrin nanostructures in photodynamic therapy. Nanomedicine 2010;5:307–17.45. Sharma S.K., Chiang L.Y., Hamblin M.R. Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine 2011;6:1813–25.Sharma S.K., Chiang L.Y., Hamblin M.R. Photodynamic therapy with fullerenes in vivo: reality or a dream? Nanomedicine 2011;6:1813–25.46. Ni J., Wu Q.Y., Li Y.G. et al. Cytotoxic and radiosensitizing effects of nano-C60 on tumor cells in vitro. J Nanoparticle Res 2008;10:643–51.Ni J., Wu Q.Y., Li Y.G. et al. Cytotoxic and radiosensitizing effects of nano-C60 on tumor cells in vitro. J Nanoparticle Res 2008;10:643–51.47. Andrievsky G., Bruskov V.I., Tykhomyrov A.A., Gudkov S.V. Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic Biol Med 2009;47:786–93.Andrievsky G., Bruskov V.I., Tykhomyrov A.A., Gudkov S.V. Peculiarities of the antioxidant and radioprotective effects of hydrated C60 fullerene nanostuctures in vitro and in vivo. Free Radic Biol Med 2009;47:786–93.48. Huang S.Q., Gao Y., Li F. et al. Synthesis of fullerene derivative C(60)-Lys and its radioprotection effects in AHH-1 cell. J Rad Res Rad Proces 2010;1:37–41.Huang S.Q., Gao Y., Li F. et al. Synthesis of fullerene derivative C(60)-Lys and its radioprotection effects in AHH-1 cell. J Rad Res Rad Proces 2010;1:37–41.49. Theriot A.C., Casey R.C., Moore V.C. et al. Dendro[C60]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells. Rad Envir Biophys 2010;49:437–45.Theriot A.C., Casey R.C., Moore V.C. et al. Dendro[C60]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells. Rad Envir Biophys 2010;49:437–45.50. Chirico F., Fumelli C., Marconi A. et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol 2007;16:429–36.Chirico F., Fumelli C., Marconi A. et al. Carboxyfullerenes localize within mitochondria and prevent the UVB-induced intrinsic apoptotic pathway. Exp Dermatol 2007;16:429–36.51. Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469–78.Dobrovolskaia M.A., McNeil S.E. Immunological properties of engineered nanomaterials. Nat Nanotechnol 2007;2:469–78.52. Cai X., Hao J., Zhang X. et al. The polyhydroxylated fullerene derivative C60(OH)24 protects mice from ionizingradiation- induced immune and mitochondrial dysfunction. Toxicol Appl Pharmacol 2010;243:27–34.Cai X., Hao J., Zhang X. et al. The polyhydroxylated fullerene derivative C60(OH)24 protects mice from ionizingradiation- induced immune and mitochondrial dysfunction. Toxicol Appl Pharmacol 2010;243:27–34.53. Injac R., Perse M., Cerne M. et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009;30:1184–96.Injac R., Perse M., Cerne M. et al. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials 2009;30:1184–96.54. Dordević A., Bogdanović G. Fullerenol – a new nanopharmaceutic? Arch Oncol 2008;16:42–5.Dordević A., Bogdanović G. Fullerenol – a new nanopharmaceutic? Arch Oncol 2008;16:42–5.55. Takada H., Kokubo K., Matsubayashi K., O evaluated by β-carotene bleaching assay. Biosci Biotechnol Biochem 2006;70: 3088–93.Takada H., Kokubo K., Matsubayashi K., O evaluated by β-carotene bleaching assay. Biosci Biotechnol Biochem 2006;70: 3088–93.56. Vávrová J., Řezáčová M., Pejchal J. Fullerene nanoparticles and their antioxidative effects: a comparison to other radioprotective agents. J Appl Biomed 2012;10:1–8.Vávrová J., Řezáčová M., Pejchal J. Fullerene nanoparticles and their antioxidative effects: a comparison to other radioprotective agents. J Appl Biomed 2012;10:1–8.57. Fourches D., Pu D., Tassa C. et al. Quantitative nanostructure-activity relationship modeling. Acs Nano 2010;4:5703–12.Fourches D., Pu D., Tassa C. et al. Quantitative nanostructure-activity relationship modeling. Acs Nano 2010;4:5703–12.58. Kayat J., Gajbhiye V., Tekade R.K., Jain N.K. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomed Nanotechnol Biol Med 2011;7:40–9.Kayat J., Gajbhiye V., Tekade R.K., Jain N.K. Pulmonary toxicity of carbon nanotubes: a systematic report. Nanomed Nanotechnol Biol Med 2011;7:40–9.59. Miller J., Lam M., Lebovitz R. Derivatized fullerenes: a new class of therapeutics and imaging agents. HeinOnline. Nanotech. L. & Bus., 2007.Miller J., Lam M., Lebovitz R. Derivatized fullerenes: a new class of therapeutics and imaging agents. HeinOnline. Nanotech. L. & Bus., 2007.60. Kepley C. Use of fullerenes for the treatment of mast cell and basophil-mediated disease. US Patent, № 7947262, 2006.Kepley C. Use of fullerenes for the treatment of mast cell and basophil-mediated disease. US Patent, № 7947262, 2006.61. Kateb B., Chiu K., Black K.L. et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?NeuroImage, 2011;54:106–24.Kateb B., Chiu K., Black K.L. et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy?NeuroImage, 2011;54:106–24.62. Bystrzejewska-Piotrowska G., Golimowski J., Urban P.L. Nanoparticles: Their potential toxicity, waste and environmental management. Waste Management 2009;29:2587–95.Bystrzejewska-Piotrowska G., Golimowski J., Urban P.L. Nanoparticles: Their potential toxicity, waste and environmental management. Waste Management 2009;29:2587–95.63. Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 2008;4:26–49.Lewinski N., Colvin V., Drezek R. Cytotoxicity of nanoparticles. Small 2008;4:26–49.